Category: BiometSyndicate content

Zimmer reveals post-Biomet merger plans

October 31, 2014 by Brad Perriello

Zimmer reveals the management team and business structure it plans to put in place once its $13 billion merger with rival Biomet closes.

Zimmer reveals post-Biomet merger plans

Biomet inks $6m deal to settle kickback charges

October 29, 2014 by Brad Perriello

Biomet agrees to pay more than $6 million to settle False Claims Act charges that it paid doctors to use its bone-growth stimulators.

Biomet inks $6m deal to settle FCA charges

Biomet paid nearly $6.1 million to settle federal charges that it paid kickbacks to doctors to induce them to use bone growth stimulators sold by its EBI subsidiary, the U.S. Justice Dept. said today.

JNJ/Synthes integration continues to bring hefty charges | The week in medtech M&A

October 22, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: JNJ continues to pay hefty integration charges on Synthes deal; Stryker: Mako sales not as strong as we hoped; ConvaTec owners appoint banks to explore sale: sources; BD buys Irish next-gen sequencing startup GenCell Biosystems; Valeant says may raise Allergan bid; beats on profit

JNJ continues to pay hefty integration charges on Synthes deal

October 16, 2014 by Brian Johnson

JNJ continues to pay hefty integration charges on Synthes deal

October 16, 2014 by Brian Johnson

More than 2½ years after it spent $21.3 billion on Synthes, Johnson & Johnson continues to take hefty charges on integrating the orthopedics company into its DePuy franchise.

JNJ continues to pay hefty integration charges on Synthes deal

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Biomet's Q1 profits plunge despite sales increases

October 9, 2014 by Brad Perriello

Profits during Biomet's fiscal 1st quarter plunge 77% despite nearly across-the-board sales increases for its orthopedic implants.

Biomet's Q1 profits plunge despite sales increases

Biomet today reported a 77% profit slide for its fiscal 1st quarter, despite posting sales gains across its all but 1 line of orthopedic implants.

Peripherals transition team named in Medtronic, Covidien merger | The week in medtech M&A

October 8, 2014 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Medtronic, Covidien name peripherals biz transition team; Medtronic is still in on Covidien buyout; The Street cheers changes to the Medtronic, Covidien deal; Zimmer adds Harvard spinout Etex Corp.; EU to extend Zimmer, Biomet probe

Medtronic, Covidien name peripherals biz transition team

October 1, 2014 by Alex Soule

EU to extend Zimmer, Biomet probe

October 2, 2014 by MassDevice

European anti-trust regulators are extending their probe into the proposed $13 billion merger of orthopedics rivals Zimmer and Biomet.

EU to extend Zimmer, Biomet probe

UPDATED Oct. 2, 2013, with comment from Zimmer.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp